Press Releases August 27, 2026 08:05 AM

Harmony Biosciences to Participate in 2026 Cantor Global Healthcare Conference

Harmony Biosciences to Present at 2026 Cantor Global Healthcare Conference

By Leila Farooq
Share
Twitter Reddit Facebook LinkedIn
HRMY

Harmony Biosciences Holdings, Inc., a pharmaceutical company focused on rare neurological diseases, announced that its management team will participate in a fireside chat at the 2026 Cantor Global Healthcare Conference on September 10, 2026, with a webcast available to investors.

Harmony Biosciences to Participate in 2026 Cantor Global Healthcare Conference
HRMY
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Harmony Biosciences will present at a major healthcare investor conference, increasing visibility among institutional investors.
  • The company focuses on innovative therapies for rare neurological diseases, a niche pharmaceutical sector with specialized market demand.
  • This presentation offers engagement with stakeholders and updates on company progress and strategy.

PLYMOUTH MEETING, Pa., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the 2026 Cantor Global Healthcare Conference in New York, N.Y., on Thursday, September 10, 2026, at 10:20 a.m., E.T.

A webcast of the fireside chat will be available on the investor page of the Harmony Biosciences website at https://ir.harmonybiosciences.com/.

About Harmony Biosciences
Harmony Biosciences is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases who have unmet medical needs. Driven by novel science, visionary thinking, and a commitment to those who feel overlooked, Harmony Biosciences is nurturing a future full of therapeutic possibilities that may enable patients with rare neurological diseases to truly thrive. Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, Pa., we believe that when empathy and innovation meet, a better future can begin; a vision evident in the therapeutic innovations we advance, the culture we cultivate, and the community programs we foster. For more information, please visit www.harmonybiosciences.com.

Harmony Biosciences Investor Contact:
Brennan Doyle
484-566-3685
[email protected]

Harmony Biosciences Media Contact:
Cate McCanless
202-641-6086
[email protected]


Risks

  • Lack of detailed financial or product updates in the announcement limits new information that could impact stock movement.
  • Dependence on successful commercialization of therapies in a competitive and regulated pharmaceutical sector.
  • Uncertainty around future product approvals and market penetration in rare disease therapeutics.

More from Press Releases

Edible Garden Awarded New Target Fresh Herb Program for Peak Holiday Season Aug 27, 2026 AZIO AI Increases Estimated Sales Pipeline to Approximately $307 Million for Up to 512 NVIDIA HGX B300 Systems in Expanded Power Champion Agreement Aug 27, 2026 BranchOut Food Inc. Announces $2.79 Million Underwritten Public Offering Aug 27, 2026 BranchOut Secures Approximately $750,000 in Initial Orders for New Front-of-Club Multipack Product Line and Dried Cheesecake Bites with Nation's Largest Warehouse Club Retailer Aug 27, 2026 Catheter Precision Achieves Major Commercial Milestones with Cardinal Health, Johns Hopkins and the placement of the First VIVO System in Germany Aug 27, 2026